## <u>Dewayne Anthony Lee Johnson</u> (DOB: 01/20/1972)

- June 11, 2012: Began job as full time Integrated Pest Manager at Benicia Unified School District. Mr. Johnson begins mixing and spraying RangerPro and Roundup Pro 20-40 times a year. He averaged 2-5 hours of spraying each day (5 schools in 5 locations); some weekend spraying of 4 hours. Drift exposures were constant and daily. Accidental spills leading to major exposures.
- Late May/Early June 2014: Mr. Johnson develops a rash over his entire body.
- July 23, 2014: Mr. Johnson visits Dr. Chanson for treatment of whole body rash. He is told his condition is not related to RangerPro based on Monsanto's Safety Data Sheet. Still Spraying
- August 26, 2014: Diagnosis: Epidermotropic T-Cell Non-Hodgkin Lymphoma; maybe MF or PTCL.
- October 3, 2014: TCR gene rearrangement positive and Dr. Ofodile diagnoses MF. CT-Scans around that time showed adenopathy in neck, groin, and axilla. Still Spraying.
- **November 3, 2014:** Starts UVB and subsequently MTX was added. UVB continues through February 2015.
- November 11, 2014: Lee Johnson telephones Monsanto to ask about link between his cancer and RangerPro/Roundup use. Daniel Goldstein, M.D. is notified but does not contact Mr. Johnson.
  Still Spraying
- **December 3, 2014:** Repeat biopsies at UCSF confirm the mycosis fungoides diagnosis.
- January 29, 2015: Another spill (Left shoulder) of RangerPro from leaky backpack sprayer.
- March 3, 2015: Seen at Stanford; stage IIB and started Targretin.
- March 20, 2015: IARC: Group 2A Classification; Roundup is "Probable Human Carcinogen"
- March 27, 2015: Call to Missouri Poison Control Center by Lee Johnson; advised his cancer is unrelated, complaint reported to Monsanto. No action from Monsanto. Still spraying
- **September 17, 2015:** Large cell transformation diagnosed by Dr. Ofodile.
- October 22, 2015: Clinical progression and started TSBET; did not tolerate INF. Still Spraying
- March-April 2016: Another course of TSBET while on Targretin.
- **September 2016-May 2017:** Brentuximab Vedotin; stopped responding.
- November 2017- January 2018: Palatrexate chemotherapy with significant toxicities.
- June 2018: Progressive disease based on PET scan shows wide-spread increased uptake.